SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-167307
Filing Date
2022-06-03
Accepted
2022-06-03 16:06:01
Documents
14
Period of Report
2022-06-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d357594d8k.htm   iXBRL 8-K 48340
2 EX-10.1 d357594dex101.htm EX-10.1 105490
3 EX-10.2 d357594dex102.htm EX-10.2 60870
  Complete submission text file 0001193125-22-167307.txt   379792

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ctic-20220601.xsd EX-101.SCH 2534
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctic-20220601_lab.xml EX-101.LAB 17986
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctic-20220601_pre.xml EX-101.PRE 11253
8 EXTRACTED XBRL INSTANCE DOCUMENT d357594d8k_htm.xml XML 3494
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 22994346
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences